FIELD: biochemistry.
SUBSTANCE: invention relates to the field of biochemistry, in particular to an antibody or its antigen-binding fragment, which specifically bind to ligand 1 of human programmed cell death receptor (hereinafter – PD-L1). An expression vector containing a nucleic acid molecule, which encodes the antibody or its antigen-binding fragment; a composition, a kit, a hybrid protein containing the specified antibody are also disclosed. A method for the treatment using the specified antibody and the use of the specified antibody when producing a drug for the treatment or prevention of hPD-L1-mediated disease are disclosed.
EFFECT: invention has the capability of effective treatment of diseases related to ligand 1 of human programmed cell death receptor (PD-L1).
46 cl, 37 dwg, 22 tbl, 32 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-PD-L1 AND IL-2 CYTOKINES | 2017 |
|
RU2769282C2 |
| ANTIBODIES TO PD-1 AND THEIR APPLICATION | 2017 |
|
RU2761640C2 |
| MOLECULES BINDING TO 4-1BB | 2011 |
|
RU2551963C2 |
| CHIMERIC ANTIGEN RECEPTORS TARGETING HER2 | 2016 |
|
RU2753695C2 |
| ANTIBODIES TO ICOS | 2016 |
|
RU2742241C2 |
| METHODS FOR TREATMENT OF SEVERE INSULIN RESISTANCE BY INTERRUPTING GLUCAGON RECEPTOR SIGNAL TRANSMISSION | 2017 |
|
RU2772508C2 |
| CD40L ANTIBODIES AND METHODS OF TREATING CD40L RELATED DISEASES AND DISORDERS | 2016 |
|
RU2727646C2 |
| ANTIBODIES AGAINST SIGNAL-REGULATORY ALPHA PROTEIN AND THEIR APPLICATION METHODS | 2017 |
|
RU2771964C2 |
| FUSED PROTEIN CONSTRUCTS FOR COMPLEMENT-RELATED DISEASE | 2019 |
|
RU2824402C2 |
| STRUCTURES HAVING SIRP-ALPHA DOMAIN OR ITS VERSION | 2016 |
|
RU2740672C2 |
